Autres langues PMV Pharmaceuticals, Inc.

Actions

PMVP

US69353Y1038

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 10/06/2024			Varia. 5j.	Varia. 1 janv.
1,7 ^USD	+2,41 %		-1,73 %	-45,16 %

29/05	PMV Pharmaceuticals et Foundation Medicine vont developper un diagnostic compagnon pour le Rezatapopt	MT
29/05	Foundation Medicine et PMV Pharma annoncent leur collaboration pour le developpement d'un diagnostic compagnon pour le Rezatapopt	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

PMV Pharmaceuticals to Participate at Upcoming Investor Conferences in June	30/05
PMV Pharmaceuticals, Foundation Medicine to Develop Companion Diagnostic for Rezatapopt	29/05
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator	29/05
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C Reactivator	29/05
Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt	29/05
PMV Pharmaceuticals Reports First Quarter 2024 Financial Results and Corporate Highlights	09/05
PMV Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors	27/03
PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors	27/03
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer	18/03
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer	18/03
North American Morning Briefing : Stock Futures -2-	06/03
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights	29/02
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference	26/02
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway	18/01
PMV Pharmaceuticals, Inc. Announces Workforce Reduction of Approximately 30%	18/01
MORNING BRIEFING - USA/Asien	08/01
PMV Pharmaceuticals Names Michael Carulli as CFO; Phase 2 Trial of Tumor Treatment on Track	05/01
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development	05/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues PMV Pharmaceuticals, Inc.

Actions

PMVP

US69353Y1038

Autres langues

Filtres